-
Product Insights
Vascular Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Vascular Injury - Drugs In Development, 2023’, provides an overview of the Vascular Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vascular Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Raynauds Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Raynauds Disease - Drugs In Development, 2023’, provides an overview of the Raynauds Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuropathy - Drugs In Development, 2023’, provides an overview of the Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Systemic Sclerosis (Scleroderma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Drugs In Development, 2023’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-552 in Musculoskeletal Inflammation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. R-552 in Musculoskeletal Inflammation Drug Details: R-552 is under development for the treatment of psoriasis, moderately...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cilnidipine + Tadalafil) in Raynauds Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cilnidipine + Tadalafil) in Raynauds Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Cilnidipine + Tadalafil) in Raynauds Disease Drug Details:Profervia is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cilnidipine + Tadalafil) in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cilnidipine + Tadalafil) in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Cilnidipine + Tadalafil) in Systemic Sclerosis (Scleroderma)Drug Details:Profervia is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cetuximab biosimilar in Lip Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab biosimilar in Lip Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab biosimilar in Lip Cancer Drug Details: Cetuximab biosimilar is...
-
Sector Analysis
Baking Ingredients (Bakery & Cereals) Market in Asia-Pacific – Outlook to 2021: Market Size, Growth and Forecast Analytics
Baking Ingredients (Bakery & Cereals) Market in Asia-Pacific - Outlook to 2021: Market Size, Growth and Forecast Analytics is a broad level market review of Baking Ingredients market of Asia-Pacific covering 5 Countries Australia, China, India, Japan and South Korea. The research handbook provides up-to-date market size data for period 2011-2016 and illustrative forecast to 2021 covering key market aspects like Sales Value and Volume for Baking Ingredients and its variants Baking Chocolate Chips & Morsels, Baking Powder/Soda, Cake Decorations...